Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

BMS Slashing 840 More Jobs

September 24, 2010 7:48 am | by Linda A. Johnson | News | Comments

Drugmaker Bristol-Myers Squibb Co. is cutting jobs again, this time eliminating about 3 percent of its positions in its latest effort to streamline operations.


Amgen Recalling Anemia Drugs Over Glass Flakes

September 24, 2010 7:44 am | News | Comments

Amgen Inc. is recalling some lots of its blockbuster Epogen and Procrit anemia treatments because the injected drugs may contain glass flakes that could cause blood clots, swelling of veins, immune system reactions and other problems.


EMA Says No to Cladribine

September 24, 2010 7:42 am | News | Comments

Merck KGaA announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a negative opinion regarding the marketing authorization application for Cladribine Tablets as a treatment for multiple sclerosis.


Dapagliflozin Improves HbA1c in Type 2 Diabetes

September 24, 2010 7:38 am | News | Comments

Bristol-Myers Squibb and AstraZeneca announced results from Phase 3 study showing that dapagliflozin was non-inferior compared to glipizide in improving HbA1c when added to existing metformin therapy during a 52-week treatment period.


Not-So-Standard Operating Procedures

September 24, 2010 6:52 am | by James DeSanti, Founder and CEO, PharmaVigilant | Articles | Comments

Standard operating procedures are a necessary evil. Although cumbersome and at times seeming to hinder more than they help, they have enabled the pharmaceutical industry to grow to the size it is today.


RTS Life Sciences Forms Pharmaceutical Testing Group

September 23, 2010 10:48 am | News | Comments

RTS Life Science, a worldwide supplier of automated sample management and pharmaceutical testing systems, has announced the formation of a Pharmaceutical Testing Group.


Image Software

September 23, 2010 8:53 am | Drug Discovery & Development | Product Releases | Comments

Lumenera Corporation, a leading manufacturer and developer of high performance digital cameras and custom imaging solutions, has announced INFINITY camera integration with Media Cybernetics Image-Pro software.


Scanning Electron Microscope

September 23, 2010 8:47 am | Product Releases | Comments

JEOL offers the InTouchScope, an analytical, low vacuum scanning electron microscope featuring integrated energy dispersive spectroscopy with the latest silicon drift detector technology.


RXi And Eyegate Partner on Ocular Delivery System

September 23, 2010 8:26 am | News | Comments

RXi Pharmaceuticals Corporation, a leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced that they will collaborate on the ocular delivery of RNAi therapeutics.


Partnership Creates European Centre for Chirality

September 23, 2010 8:23 am | News | Comments

Ghent University, the University of Antwerp, and BioTools Europe Ltd have announced the creation of the European Centre for Chirality. EC2 brings together leading authorities dedicated to advancing the understanding the role chirality plays in biological processes.


New Heart Valve Can Be Installed Without Cracking Chest

September 23, 2010 8:16 am | by Lauran Neergaard | News | Comments

Thousands of older Americans who need new heart valves but are too frail to survive the surgery might soon get a chance at an easier option - a way to thread in an artificial aortic valve without cracking their chests.


Care Improved At US Hospitals

September 23, 2010 8:11 am | News | Comments

A report says treatment has improved substantially at U.S. hospitals for several ailments including heart attacks, pneumonia and children's asthma.


Abbott And Reata to Develop Bardoxolone

September 23, 2010 8:09 am | News | Comments

Abbott and Reata Pharmaceuticals announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl, which is currently in late Phase 2 trials for the treatment of chronic kidney disease.


Tolerx Enrolls First Patient in Phase 3 Trial

September 23, 2010 8:06 am | News | Comments

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced the presentation of preclinical research describing the mechanism of action of otelixizumab.


Avandia Pulled In Europe, Restricted In US

September 23, 2010 7:50 am | by Matthew Perrone | News | Comments

European health regulators have banned sales of the once-blockbuster diabetes drug Avandia because of evidence it raises the risk of heart attack, but doctors in the U.S. will be able to continue prescribing it with some significant restrictions.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.